Cogent Biosciences Current Cash

Cogent Biosciences (COGT) currently reports a current cash of $240M as of March 2026. That compares with $130M in the prior-year period — up 91.4% year over year. Use the charts on this page to explore Cogent Biosciences's current cash history and peer comparisons.

Cogent Biosciences's current cash increased from $130M to $240M — a 91.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cogent Biosciences reported $240M in current cash as of March 2026. That compares with $130M in the prior-year period — up 91.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $240M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cogent Biosciences, and consider following COGT for alerts when major investors trade the stock.

Cogent Biosciences is classified in the Healthcare sector. On current cash, it currently shows $240M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing COGT with unrelated industries.